Stryker receives FDA 510(k) clearance for bone tumor ablation system
Click Here to Manage Email Alerts
Stryker has announced FDA 510(k) clearance for its OptaBlate bone tumor ablation system for patients with metastatic cancer, according to a press release.
The OptaBlate system is designed with microinfusion technology to keep the surgical area hydrated and help prevent charring, according to the release.
“Our commitment to our customers and understanding their needs has never been stronger. The collaboration has helped us to develop a more efficient bone tumor ablation system to address their unmet needs,” Greg Siller, vice president and general manager of Stryker’s interventional spine business, said in the release. “OptaBlate will help our customers provide another treatment option for those suffering from painful metastatic cancer, and this is just the beginning.”
According to the release, Stryker will debut the OptaBlate at the North American Spine Society Annual Meeting from Oct. 12, 2022, to Oct. 15, 2022, in Chicago.
Read more about
Click Here to Manage Email Alerts